Bard's Gamble on Restructuring
Executive Summary
Troubled with severe price pressures, Bard undertakes a major restructuring.
You may also be interested in...
Tyco Buys Bard, While Medtronic Scoops Up MiniMed
Tyco's acquisition of CR Bard and Medtronic's purchase of MiniMed were announced almost simultaneously, but they hardly are true representations of ongoing consolidation in the medical device industry. Tyco bought Bard for manufacturing and distribution synergies, and Tyco officials talked about leveraging Bard as a growth platform in a slow-growth industry. Medtronic bought insulin pump maker MiniMed to expand into a significantly growing field in which it hasn't yet participated.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.